Effects of short term beta adrenoreceptor blockade on serum lipids and lipoproteins in patients with hypertension or coronary artery disease

M B MURPHY, D SUGRUE,* I TRAYNER, S KAUFMAN, H YASUHARA,† C T DOLLERY, G R THOMPSON

From the Departments of Clinical Pharmacology, Cardiology, and Chemical Pathology, Royal Postgraduate Medical School; and the Medical Research Council Lipoprotein Team, Hammersmith Hospital, London

SUMMARY The effects of beta adrenergic receptor blockade with propranolol or pindolol on serum total cholesterol, low density lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL), and its subfractions HDL₂ and HDL₃, serum triglyceride, and Intralipid clearance were studied in 17 normolipidaemic, non-diabetic patients with hypertension or angina pectoris. Both pindolol and propranolol had similar effects on fasting serum total and lipoprotein cholesterol concentrations. HDL₂ cholesterol concentrations were reduced by 9±29% and HDL₃ cholesterol increased by 11±16%, but there were no significant changes in total or LDL cholesterol in the combined groups after six weeks' treatment. After 12 weeks' treatment total cholesterol concentrations were reduced by 7±10% mainly owing to a reduction in the LDL fraction of 9±15%. Concentrations of HDL₂ remained low, 8% less than control values. Serum triglyceride concentrations were increased by both drugs at six weeks but had returned to base values in the pindolol group by the twelfth week. Pindolol, but not propranolol, enhanced the rate of clearance of intravenous Intralipid.

The failure to show a reduction in coronary artery morbidity in several large studies of antihypertensive treatment has raised the possibility that the metabolic side effects of the drugs used could negate the benefits of blood pressure reduction. Diuretics, the most widely used agents, promote glucose intolerance and hypokalaemia and increase serum uric acid and both serum cholesterol and triglyceride concentrations. Although beta receptor blockers have not been studied as extensively, they have been reported to raise serum concentrations of triglycerides and to reduce those of high density lipoprotein cholesterol, effects which may theoretically increase the risk of coronary artery disease. Since these drugs are now prescribed for life in young patients with mild hypertension, even small alterations in these cardiovascular risk factors could have adverse consequences in the long term. Even though only controlled prospective studies can test this hypothesis, it would seem prudent to use only those drugs with the fewest effects on lipoprotein metabolism.

Since the initial report that long term treatment with propranolol increased serum triglycerides and decreased serum free fatty acids, there have been numerous studies of the effects of beta blockers on serum lipid fractions. Differences in the drugs studied and the doses used, the inclusion of patients with hyperlipidaemia, the concurrent use of other drugs, and variation in the duration of treatment have, however, led to conflicting and confusing results (for review see Johnson). In addition, none has examined the effects of beta blockade on high density lipoprotein (HDL) cholesterol subfractions, one of which (HDL₂) is emerging as an even better predictor of coronary artery disease than total or HDL cholesterol.

In this study we examined the effects of beta blockade acutely and during three months' treatment in patients with hypertension or angina pectoris who were otherwise healthy and untreated. Since some earlier studies suggested that drugs possessing partial

Requests for reprints to Dr M B Murphy, Department of Clinical Pharmacology, Royal Postgraduate Medical School, Hammersmith Hospital, DuCane Road, London W12 0HS.

*Present address: Department of Cardiology, The Mayo Clinic, Rochester, Minnesota, USA.
†Present address: Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.

Accepted for publication 26 January 1984
agonist or intrinsic sympathomimetic activity might have smaller effects on serum lipids\textsuperscript{16-18} we compared the effects of two beta receptor blocking drugs, propranolol and pindolol, only one of which, pindolol, has partial agonist activity.

Patients and methods

Twenty two patients with mild essential hypertension or symptomatic coronary heart disease consented to participate in the study. Patients with known diabetes mellitus, hyperlipidaemia, asthma, hepatic or renal impairment, or other serious systemic disease were excluded. After five weeks taking a placebo the patients were investigated after an overnight fast. Weight, height, blood pressure, and peak expiratory flow rate were measured. A 19 gauge butterfly needle was inserted in an antecubital vein on each forearm and patency maintained with sodium citrate. A 20 ml blood sample was drawn for measurement of serum triglyceride, total cholesterol, and HDL cholesterol concentrations. An intravenous fat tolerance test was then performed. Intralipid (Kabi Vitrum) 10\% (1 ml/kg) was infused during one minute, and 5 ml blood samples were drawn from the opposite cannula at 5 minute intervals for the next 30 minutes. The patients continued to take a placebo for a further week, after which they were randomly assigned to receive propranolol 160 mg or pindolol 10 mg twice daily in a double blind fashion. They underwent further tests, identical to those with the placebo, two hours after the first dose of the beta receptor blocking agent and again after six and 12 weeks of treatment. They were requested not to alter their dietary, smoking, or drinking habits for the duration of the study.

Serum triglyceride concentrations were measured by an enzymatic method using a Technicon autoanalyzer (method No SE4-0039 PE6). To measure the HDL cholesterol, low density lipoprotein (LDL) and very low density lipoprotein cholesterol (VLDL) were first precipitated in an aliquot of serum using heparin and manganese chloride.\textsuperscript{19} One aliquot of the supernatant was used for cholesterol analysis, while dextran sulphate was added to another to precipitate the HDL\textsubscript{3} fraction.\textsuperscript{20} The cholesterol content of the resulting supernatant, comprising the HDL\textsubscript{3} fraction, was then determined. HDL\textsubscript{2} cholesterol was derived by calculating the difference between the total HDL and the HDL\textsubscript{2} cholesterol concentrations. Cholesterol was measured by an enzymatic method using the Technicon autoanalyzer (Method No SE4-0065 FB1). LDL cholesterol was calculated by the method of Friedewald et al.\textsuperscript{21} Serum opalescence after Intralipid administration was measured by spectrophotometry.\textsuperscript{22}

All patients gave informed consent and the protocol was approved by the research ethics committee of these institutions. Results are expressed as means ± standard deviation. Paired t tests were used to compare within treatment data and unpaired tests to compare the effects of the two drugs. Linear regression analysis was used to correlate variables.

Results

Seventeen of the 22 patients completed the study. Of the remainder, one was withdrawn because of nightmares and another because of poor blood pressure control requiring additional treatment and three withdrew for personal reasons. The pretreatment characteristics of those who completed the study are listed in Table 1. There were no significant differences between the two treatment groups in age, weight, or pretreatment blood pressure. Both had similar concentrations of total cholesterol, LDL, HDL, and HDL\textsubscript{2}/HDL\textsubscript{3} ratios before treatment (Table 2). Those treated with pindolol, however, had significantly lower triglyceride clearance rates and paradoxically lower serum triglyceride concentrations than those treated with propranolol.

### Table 1 Characteristics of patients treated with either propranolol or pindolol. Values are means ±SD

<table>
<thead>
<tr>
<th></th>
<th>Propranolol</th>
<th>Pindolol</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of patients</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>46±12</td>
<td>43±13</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>6/3</td>
<td>7/1</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>73.7±18.1</td>
<td>78.2±12.2</td>
</tr>
<tr>
<td>Blood pressure (mm Hg)</td>
<td>148±17/96±7</td>
<td>138±18/96±12</td>
</tr>
</tbody>
</table>

Since pindolol and propranolol had similar effects on serum total and lipoprotein cholesterol throughout the study (Fig. 1) the cholesterol data of the combined groups are reported. Total serum cholesterol was unchanged at the sixth week but was reduced by 7±10\% (p<0.01) at the twelfth week of treatment, mainly owing to a reduction of 9±15\% in the LDL fraction (Fig. 2). Although there was a small but significant increase in HDL cholesterol concentration after the first dose the values at six and 12 weeks were similar to those after placebo. Despite this stability of HDL cholesterol during long term treatment there were significant changes in its constituent subfractions. HDL\textsubscript{2} cholesterol was reduced by 9±23\% (p<0.05) at six weeks and remained low at 12 weeks. On the other hand HDL\textsubscript{3} was increased at six weeks (11±16\%, p<0.05), but this increase had disappeared by 12 weeks. Thus at six weeks HDL\textsubscript{2} carried only 31±12\% of the cholesterol in HDL in contrast to 36±13\% (p<0.02) before beta receptor blockade, and the ratio of HDL\textsubscript{2} to HDL\textsubscript{3} was reduced from 0.63±0.34 to 0.5±0.25 (p<0.02).

The initial changes in serum triglyceride concentrations were minimal after both drugs (Fig. 2), but at
Beta adrenoceptor blockade and serum lipoproteins

Table 2  Effects of beta blocking agents on serum lipid concentrations (mmol/l) in patients treated with either propranolol (n=9) or pindolol (n=8). Values are means ±SD

<table>
<thead>
<tr>
<th></th>
<th>Propranolol</th>
<th></th>
<th></th>
<th>Pindolol</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Basal</td>
<td>First dose</td>
<td>6 weeks</td>
<td>12 weeks</td>
<td>Basal</td>
<td>First dose</td>
</tr>
<tr>
<td>Serum cholesterol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>concentration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>6.04±0.99</td>
<td>6.04±1.18</td>
<td>6.20±1.18</td>
<td>5.66**±0.86</td>
<td>5.30±0.54</td>
<td>5.99±0.46</td>
</tr>
<tr>
<td>LDL</td>
<td>4.35±0.87</td>
<td>4.23±0.99</td>
<td>4.45±1.15</td>
<td>3.98**±0.81</td>
<td>3.81±0.61</td>
<td>3.40±0.51</td>
</tr>
<tr>
<td>HDL</td>
<td>1.4±0.37</td>
<td>1.54±0.35</td>
<td>1.44±0.42</td>
<td>1.37±0.30</td>
<td>1.29±0.39</td>
<td>1.36±0.40</td>
</tr>
<tr>
<td>HDL2</td>
<td>0.55±0.34</td>
<td>0.62±0.33</td>
<td>0.48±0.29</td>
<td>0.46±0.18</td>
<td>0.49±0.26</td>
<td>0.48±0.26</td>
</tr>
<tr>
<td>HDL3</td>
<td>0.85±0.13</td>
<td>0.92±0.16</td>
<td>0.96±0.22</td>
<td>0.90±0.20</td>
<td>0.80±0.18</td>
<td>0.88±0.21</td>
</tr>
<tr>
<td>HDLtotal/HDL</td>
<td>0.32±0.11</td>
<td>0.37±0.14</td>
<td>0.32±0.13</td>
<td>0.33±0.10</td>
<td>0.34±0.14</td>
<td>0.39±0.17</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>0.65±0.40</td>
<td>0.70±0.37</td>
<td>0.51±0.27</td>
<td>0.53±0.23</td>
<td>0.61±0.26</td>
<td>0.55±0.29</td>
</tr>
<tr>
<td>concentrations</td>
<td>1.45±0.97</td>
<td>1.33±0.83</td>
<td>1.59±0.87</td>
<td>1.56±0.84</td>
<td>1.03±0.48</td>
<td>1.10±0.52</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>5.3±1.9</td>
<td>5.5±2.1</td>
<td>5.7±2.8</td>
<td>4.4±1.4</td>
<td>2.9±1.7</td>
<td>4.4±3.4</td>
</tr>
<tr>
<td>clearance (%)/min</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*p<0.05; **p<0.01.
HDL, high density lipoprotein; LDL, low density lipoprotein.

six weeks they had increased by 21±39% (p<0.01) in the combined groups (Fig. 1). By the twelfth week, however, they had returned to baseline values in the pindolol group, although they remained raised in those treated with propranolol (Table 2). Whereas the rate of clearance of infused triglycerides was not altered by propranolol it was significantly enhanced in

![Fig. 1 Changes in serum lipid concentrations after (a) the first dose and (b) six and (c) 12 weeks' treatment with propranolol (n=9) and pindolol (n=8). Values are means ±SEM. HDL, high density lipoprotein; LDL, low density lipoprotein.](image)

![Fig. 2 Changes in serum lipid concentrations after the first dose of beta receptor blocking agent and after six weeks' and 12 weeks' treatment with pindolol or propranolol (n=17). Values are means ±SEM. *p<0.05; **p<0.01. HDL, high density lipoprotein; LDL, low density lipoprotein.](image)

those treated with pindolol: this latter group had slower fractional clearance rates initially, but these rose during treatment from 2.9±1.7 to 3.9±1.2% per min after six weeks (p<0.03) and to 4.5±2.6% min after 12 weeks (Table 2). There was, however, no correlation between changes in serum triglyceride concentrations and in Intralipid clearance rates. Whereas basal serum triglyceride correlated negatively both with HDL (r=-0.63, p<0.01) and HDL2 (r=-0.71, p<0.01), there were no correlations between the changes in triglyceride concentrations and in HDL or HDL2 at six weeks (r=-0.049 and -0.185 respectively) or at 12 weeks (r=-0.173 and -0.138 respectively).

The effects of both drugs on blood pressure and heart rate are shown in Fig. 3. Whereas propranolol caused a significant bradycardia (from 77±11 to 57±7
beats/min at 12 weeks) the reduction in resting heart rate after pindolol (from 77±13 to 69±6 beats/min) was considerably less. Neither drug affected peak expiratory flow rate, and there were no significant changes in body weight in either group.

Discussion

In this study significant changes occurred in serum lipid concentrations during three months' beta adrenoceptor blockade. Whereas some changes were already known (the increase in serum triglyceride and reduction in cholesterol concentrations), this is the first report that beta adrenergic blocking agents may influence HDL subfractions. Both propranolol and pindolol caused similar changes in fasting total and HDL cholesterol concentrations, but pindolol, unlike propranolol, accelerated triglyceride clearance. Although the numbers of patients studied were small and caution is needed when interpreting differences between the two drugs, it is unlikely that partial agonist activity substantially influences the response of serum lipid concentrations to beta receptor blockade in normolipidaemic subjects.

Early work on the metabolic effects of hypotensive drugs was confined to examining changes in serum total cholesterol and triglyceride concentrations, but more recent studies have focussed on changes in HDL cholesterol concentration since this correlates strongly and inversely with the risk of vascular disease. Most workers, but not all,23-25 have found a reduction in HDL cholesterol with beta receptor blockers. Although HDL cholesterol remained unchanged in our patients there was a significant reduction in its quantitatively minor subfraction HDL2. The latter, rather than total HDL, has the strongest negative correlation with the extent of coronary artery disease in angiographic studies.13 HDL2 cholesterol is present in higher concentrations in women,26 who have a lower prevalence of vascular disease than men, and is increased by moderate alcohol intake27 and exercise,28 which may protect against vascular disease. Conversely, smoking restricts the normal postprandial increase in HDL2 cholesterol.29 In contrast to the reduction in HDL2 cholesterol we also found a potentially beneficial reduction in LDL cholesterol, whose concentration correlates positively with the presence of vascular disease.13 This decrease was slower in onset than that of HDL2, since it was not evident at the sixth week, but in percentage terms was comparable in extent. Similar reductions have been reported previously after propranolol9,10,23 and acebutolol,23 whereas considerable prognostic importance has been attributed to the reduction in HDL cholesterol by beta blocking agents, less attention has been given to their ability to reduce LDL, which could theoretically offset the former's effects.

The initial increase in serum triglyceride concentrations confirms the findings of most previous studies14; longer term studies have shown that these increases in response to beta blockade tend to persist. Waal-Manning reported a continuing increase in triglyceride concentration after one year's treatment with metoprolol,30 whereas Schumlan et al found raised values after one year in patients taking propranolol in the BHAT trial.31 The present study confirmed the persisting increase in triglyceride concentrations after three months' treatment with propranolol but not with pindolol: indeed this was the only noticeable difference between the two drugs, although poor matching of the groups with respect to pretreatment Intralipid clearance and fasting triglyceride concentrations limits interpretation of its clinical significance. Nevertheless, the similarities in the triglyceride response to pindolol in this study and in the Oslo trial,15 in which there was a small, albeit statistically non-significant, increase in triglyceride concentration at 12 weeks, suggests that the acute and long term effects of this beta receptor blocking agent may differ.

A primary aim of this study was to clarify the mechanism by which beta adrenoceptor blockade alters serum lipid concentrations. The proposal that
Beta adrenoceptor blockade and serum lipoproteins

the effects were mediated through inhibition of lipoprotein lipase in vascular endothelium was of particular interest since it would explain not only the increase in triglyceride concentrations but also the reductions in HDL₂ and LDL cholesterol seen in this study. VLDL catabolism by lipoprotein lipase in adipose and muscle tissue results in the formation of LDL and in the release of surface components which contribute to the conversion of HDL₂ to HDL₃. Unlike Day et al., however, we found no reduction in Intralipid clearance, an index of lipoprotein lipase activity, in our patients during beta receptor blockade. The increase in triglyceride concentration in the propranolol group was not accompanied by a decrease in the rate of Intralipid clearance, whereas the small increase in triglyceride at six weeks in the pindolol group occurred despite appreciable acceleration of the clearance of Intralipid. Furthermore, whereas there were significant inverse relations between basal triglyceride, HDL cholesterol, and HDL₂ cholesterol concentrations in the whole group, changes in these indices did not correlate, as would be expected if lipoprotein lipase were inhibited by beta receptor blockade. This, coupled with the evidence that lipoprotein lipase activity in adipose tissue biopsy specimens from patients treated with propranolol is increased, suggests that beta receptor blockade may promote triglyceride synthesis rather than inhibit its catabolism.

In conclusion, the serum cholesterol changes in this study were small and their long term prognostic significance uncertain. Reduction in HDL₂ cholesterol concentrations may be detrimental, but the concomitant reduction in LDL could offset this. Similarly, small increases in triglyceride concentrations by themselves are unlikely to contribute to vascular morbidity. The mechanism of changes in serum lipids induced by beta blocking agents remains unclear in that we found no evidence that triglyceride clearance was inhibited by propranolol, although it was apparently improved by pindolol.

References

6 Edmonds CJ, Jasani B. Total-body potassium in hypertensive patients during prolonged diuretic therapy. Lancet 1972; ii: 8–12.


Effects of short term beta adrenoreceptor blockade on serum lipids and lipoproteins in patients with hypertension or coronary artery disease.

M B Murphy, D Sugrue, I Trayner, S Kaufman, H Yasuhara, C T Dollery and G R Thompson

*Br Heart J* 1984 51: 589-594
doi: 10.1136/hrt.51.6.589

Updated information and services can be found at:
[http://heart.bmj.com/content/51/6/589](http://heart.bmj.com/content/51/6/589)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)